アレルギー性鼻炎 - 市場考察、疫学、市場予測（2032年）

主なハイライト

• 主要7市場のアレルギー性鼻炎（AR）の総患者数は2022年に1億7,800万人と推定されています。このうち米国は4,600万人であるのに対し、欧州4ヶ国・英国は約6,800万人です。米国では、これらの症例の54%が診断されています。
• アレルギー性鼻炎（AR）の市場規模は、2022年に主要7市場の中で米国がもっとも大きく、約34億9,600万米ドルを占め、2032年までにさらに拡大する見込みです。
• 調査期間中（2019年～2032年）に市場に登場する可能性のある製品には、Grass MATA MPLやREGN5713-5714-5715などがあります。

当レポートでは、アレルギー性鼻炎（AR）の主要7市場について調査分析し、市場規模と予測、現在の治療法と新薬の情報などを提供しています。

目次

第1章 主要考察

第2章 レポートのイントロダクション

第3章 AR市場の概要

• ARの市場シェア分布（2019年）
• ARの市場シェア分布（2032年）

第4章 疫学と市場予測手法

第5章 主な出来事

第6章 ARのエグゼクティブサマリー

第7章 アレルギー性鼻炎（AR）の疾患の背景と概要

• イントロダクション
• 鼻炎の分類
• 病因
• 病因
• 兆候と症状
• アレルギー性鼻炎（AR）の合併症
• 診断
  • 鑑別診断
  • 診断ガイドライン
• 治療
  • 治療ガイドライン

第8章 ARの疫学と患者人口

• 主な調査結果
• 前提条件と根拠：主要7市場
  • 米国
  • 欧州4ヶ国・英国
  • 日本
• 主要7市場のアレルギー性鼻炎（AR）の総症例数
• 主要7市場のアレルギー性鼻炎（AR）の診断された総症例数
• 米国
• 欧州4ヶ国・英国
• 日本

第9章 ペイシェントジャーニー

第10章 上市済み薬品

• 主な競合
• Sublivac: HAL Allergy Ltd.
• Rupafin (Rupatidine fumarate ): Teikoku Seiyaku/Uriach
• Allesaga Tape (Emedastine fumarate ): Hisamitsu Pharmaceutical
• Xolair (Omalizumab): Novartis Pharmaceuticals
• Odactra/Acarizax/Miticure (House dust mite allergy immunotherapy [HDM SLIT-tablet]): ALK-Abello
• Itulazax (SQ tree SLIT-tablet): ALK-Abello
• Ragwitek/Ragwizax (Short Ragweed Pollen Allergen Extract): ALK-Abello
• Cedarcure (Japanese Cedar Pollen Sublingual Tablets/TO-206): Torii Pharmaceutical/ALK-Abello
• Actair (STG320): Stallergenes Greer
• Bilaxten/Bilanoa (Bilastine): FAES Farma/Taiho Pharmaceuticals
• Ryaltris (Olopatadine Hydrochloride and Mometasone Furoate Monohydrate Nasal Spray): Glenmark Pharmaceuticals Inc.

第11章 新薬

• 主な競合
• MG01 + T517: Inmunotek
• Norketotifen (NKT): Emergo Therapeutics
• B244 suspension (AOB201): AOBiome LLC
• REGN5713-5714-5715: Regeneron Pharmaceuticals
• IRL201104: Revolo Biotherapeutics
• MM09-MG01: Inmunotek
• Grass MATA MPL: Allergy Therapeutics
• MG01-T521: Inmunotek S.L
• MG56: Inmunotek S.L
• Birch MATA MPL: Allergy Therapeutics

第12章 AR：主要7市場の分析

• 主な調査結果
• 市場見通し
• 主な市場予測の前提条件
• 属性分析
• 主要7市場のARの市場規模
• 主要7市場のARの市場規模：治療法別
• 米国のARの市場規模
  • ARの総市場規模
  • ARの市場規模：治療法別
• 欧州4ヶ国・英国のARの市場規模
• 日本のARの市場規模

第13章 KOLの見解

第14章 SWOT分析

第15章 アンメットニーズ

第16章 市場参入と償還

• 米国
• 欧州4ヶ国・英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • 英国
• 日本

第17章 付録

第18章 DelveInsightのサービス内容

第19章 免責事項

List of Tables

• Table 1: Key Events
• Table 2: Summary of Allergic Rhinitis Market and Epidemiology (2019-2032)
• Table 3: Classification of Rhinitis
• Table 4: Key Recommendations for Practice
• Table 5: Evidence Levels for Grades of Evidencea
• Table 6: Guideline Definitions for Evidence-based Statements
• Table 7: Correspondence Between The Evaluation of the Literature and the Grade of the Recommendations
• Table 8: Allergen Avoidance Measures and Their Effectiveness
• Table 9: Correspondence Between The Evaluation of the Literature and the Grade of the Recommendations
• Table 10: Treatment of Allergic Rhinitis
• Table 11: Total Prevalent Cases of Allergic Rhinitis in the 7MM in '000s (2019-2032)
• Table 12: Diagnosed Prevalent Cases of Allergic Rhinitis in the 7MM in '000s (2019-2032)
• Table 13: Prevalent Cases of Allergic Rhinitis in the United States in '000s (2019-2032)
• Table 14: Diagnosed Prevalent Cases of Allergic Rhinitis in the United States in '000s (2019-2032)
• Table 15: Age-specific Diagnosed Prevalent Cases of Allergic Rhinitis in the United States in '000s (2019-2032)
• Table 16: Severity-specific Diagnosed Prevalent Cases of Allergic Rhinitis in the United States in '000s (2019-2032)
• Table 17: Allergen-specific Diagnosed Prevalent Cases of Allergic Rhinitis in the United States in '000s (2019-2032)
• Table 18: Prevalent Cases of Allergic Rhinitis in EU4 and the UK in '000s (2019-2032)
• Table 19: Diagnosed Prevalent Cases of Allergic Rhinitis in EU4 and the UK in '000s (2019-2032)
• Table 20: Age-specific Diagnosed Prevalent Cases of Allergic Rhinitis in EU4 and the UK, in '000' (2019-2032)
• Table 21: Severity-specific Diagnosed Prevalent Cases of Allergic Rhinitis in EU4 and the UK, in '000' (2019-2032)
• Table 22: Allergen-specific Diagnosed Prevalent Cases of Allergic Rhinitis in EU4 and the UK, in '000' (2019-2032)
• Table 23: Prevalent Cases of Allergic Rhinitis in Japan in '000s (2019-2032)
• Table 24: Diagnosed Prevalent Cases of Allergic Rhinitis in Japan in '000s (2019-2032)
• Table 25: Age-specific Diagnosed Prevalent Cases of Allergic Rhinitis in Japan in '000s (2019-2032)
• Table 26: Severity-specific Diagnosed Prevalent Cases of Allergic Rhinitis in Japan in '000s (2019-2032)
• Table 27: Allergen-specific Diagnosed Prevalent Cases of Allergic Rhinitis in Japan in '000s (2019-2032)
• Table 28: MM09-MG01, Clinical Trial Description, 2021
• Table 29: Xolair (Omalizumab), Clinical Trial Description, 2023
• Table 30:: Odactra/Acarizax/Miticure (House dust mite allergy immunotherapy [HDM SLIT-tablet]), Clinical Trial Description, 2023
• Table 31: Itulazax (SQ tree SLIT-tablet), Clinical Trial Description, 2023
• Table 32: Ragwitek/Ragwizax (Short Ragweed Pollen Allergen Extract), Clinical Trial Description, 2023
• Table 33: Actair (STG320), Clinical Trial Description, 2023
• Table 34: Bilaxten/Bilanoa (Bilastine), Clinical Trial Description, 2023
• Table 35: Ryaltris (Olopatadine Hydrochloride and Mometasone Furoate Monohydrate Nasal Spray), Clinical Trial Description, 2023
• Table 36: Grastek/Grazax (Grass pollen allergy vaccine tablet), Clinical Trial Description, 2023
• Table 37: Comparison of Emerging Drugs for Treatment
• Table 38: 10,000 MG01 + 10,000 T517, Clinical Trial Description, 2023
• Table 39: Norketotifen, Clinical Trial Description, 2023
• Table 40: B244, Clinical Trial Description, 2023
• Table 41: REGN 5713-5714-5715, Clinical Trial Description, 2023
• Table 42: IRL201104, Clinical Trial Description, 2023
• Table 43: MM09-MG01, Clinical Trial Description, 2021
• Table 44: Grass MATA MPL (G306), Clinical Trial Description, 2021
• Table 45: MG01-T521,Clinical Trial Description, 2021
• Table 46: MG56, Clinical Trial Description, 2021
• Table 48: Key Market Forecast Assumptions for REGN5713-5714-5715
• Table 49: Key Market Forecast Assumptions for Grass MATA MPL (G306)

List of Figures

• Figure 1: Classification of Allergic Rhinitis According to Symptom Duration and Severity
• Figure 2: Types of Allergic Rhinitis
• Figure 3: Pathogenesis of Allergic Rhinitis
• Figure 4: Signs and Symptoms of Allergic rhinitis
• Figure 5: Complications of Allergic Rhinitis
• Figure 6: Skin Prick Test
• Figure 7: Nasal Allergen Challenges (NAC)
• Figure 8: Diagnostic Algorithm of Allergic Rhinitis
• Figure 9: Flowchart From Diagnosis to Treatment
• Figure 10: Intranasal Steroids
• Figure 11: Sublingual and Subcutaneous Immunotherapy
• Figure 12: Treatment Algorithm of Allergic Rhinitis
• Figure 13: Recommendations for Adding a Second Medication to Treat Allergic Rhinitis
• Figure 14: Rhinitis Treatment Algorithm
• Figure 15: Total Prevalent Cases of Allergic Rhinitis in the 7MM in '000s (2019-2032)
• Figure 16: Diagnosed Prevalent Cases of Allergic Rhinitis in the 7MM in '000s (2019-2032)
• Figure 17: Prevalent Cases of Allergic Rhinitis in the United States in '000s (2019-2032)
• Figure 18: Diagnosed Prevalent Cases of Allergic Rhinitis in the United States in '000s (2019-2032)
• Figure 19: Age-specific Diagnosed Prevalent Cases of Allergic Rhinitis in the United States in '000s (2019-2032)
• Figure 20: Severity-specific Diagnosed Prevalent Cases of Allergic Rhinitis in the United States in '000s (2019-2032)
• Figure 21: Allergen-specific Prevalent Cases of Allergic Rhinitis in the United States in '000s (2019-2032)
• Figure 22: Prevalent Cases of Allergic Rhinitis in EU4 and the UK in '000s (2019-2032)
• Figure 23: Diagnosed Prevalent Cases of Allergic Rhinitis in EU4 and the UK in '000s (2019-2032)
• Figure 24: Age-specific Diagnosed Prevalent Cases of Allergic Rhinitis in EU4 and the UK in '000s (2019-2032)
• Figure 25: Severity-specific Diagnosed Prevalent Cases of Allergic Rhinitis in EU4 and the UK in '000s (2019-2032)
• Figure 26: Allergen- specific Diagnosed Prevalent Cases of Allergic Rhinitis in EU4 and the UK in '000s (2019-2032)
• Figure 27: Prevalent Cases of Allergic Rhinitis in Japan in '000s (2019-2032)
• Figure 28: Diagnosed Prevalent Cases of Allergic Rhinitis in Japan in '000s (2019-2032)
• Figure 29: Age-specific Diagnosed Prevalent Cases of Allergic Rhinitis in Japan in '000s (2019-2032)
• Figure 30: Severity-specific Diagnosed Prevalent Cases of Allergic Rhinitis in Japan in '000s (2019-2032)
• Figure 31: Allergen-specific Prevalent Cases of Allergic Rhinitis in Japan in '000s (2019-2032)
• Figure 32: Patient Journey
• Figure 33: Unmet Needs
• Figure 34: Health Technology Assessment
• Figure 35: Reimbursement Process in Germany
• Figure 36: Reimbursement Process in France
• Figure 37: Reimbursement Process in Italy
• Figure 38: Reimbursement Process in Spain
• Figure 39: Reimbursement Process in the United Kingdom
• Figure 40: Reimbursement Process in Japan

Key Highlights:

• The total number of diagnosed prevalent AR patients in the 7MM were estimated to be 178 million in 2022. Out of this, the US has 46 million cases whereas EU4 and the UK has around 68 million cases. In the US, 54% of these cases are diagnosed.
• In 2022, the market size of Allergic Rhinitis was highest in the US among the 7MM, accounting for approximately USD 3,496 million which is further expected to increase by 2032.
• Some of the products that are likely to hit the market during our study period 2019-2032 include Grass MATA MPL and REGN5713-5714-5715.

DelveInsight's "Allergic Rhinitis (AR)- Market Insights, Epidemiology and Market Forecast- 2032" report delivers an in-depth understanding of the Allergic Rhinitis, historical and forecasted epidemiology as well as the Allergic Rhinitis market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Allergic Rhinitis (AR) market report provides current treatment practices, emerging drug, market size and market share of the individual therapies, current and forecasted 7MM from 2019 to 2032. The report also covers current Allergic Rhinitis treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2019-2032.

Allergic Rhinitis (AR) Disease Understanding and Treatment Algorithm

Allergic rhinitis (AR) is an atopic disease presenting symptoms of sneezing, nasal congestion, clear rhinorrhea, and nasal pruritis. It is an IgE-mediated immune response against inhaled antigens in the immediate phase, with a subsequent leukotriene-mediated late phase. This activity describes the evaluation and treatment of allergic rhinitis and highlights the role of the inter-professional team in improving care for patients with this condition.

Allergic Rhinitis (AR) Diagnosis

The most common diagnostic tests for allergic rhinitis are the percutaneous skin test and the allergen-specific immunoglobulin E (IgE) antibody test. Less common diagnostic tools include nasal provocation testing, nasal cytology (e.g., blown secretions, scraping, lavage, biopsy), naso-laryngoscopy, and intradermal skin testing.

Further details related to country-based variations are provided in the report.

Allergic Rhinitis (AR) Treatment

The treatment goal for allergic rhinitis is to relieve symptoms. Therapeutic options to achieve this goal include avoidance measures, nasal saline irrigation, oral antihistamines, intranasal corticosteroids, combination intranasal corticosteroid/antihistamine sprays; leukotriene receptor antagonists (LTRAs), and allergen immunotherapy. ,

Therapies approved in the 7MM include XOLAIR by Novartis Pharmaceuticals (Japan), ODACTRA/ACARIZAX/MITICURE (SLIT-tablet) by ALK-Abello, GRASTEK/GRAZAX (Grass pollen allergy vaccine tablet) by ALK-Abello, ITULAZAX, RAGWITEK/RAGWIZAX, CEDARCURE by ALK-Abello, Stallergenes Greer's ACTAIR (STG320) and ORALAIR, Glenmark Pharmaceuticals' (RYALTRIS), BILAXTEN/BILANOA by FAES Farma/Taiho Pharmaceutical, RUPAFIN by Mitsubishi Tanabe Pharma Corporation, DESALEX by Kyorin Pharmaceutical Co, and ALLESAGA TAPE by Hisamitsu Pharmaceutical Co., Inc.

A high unmet need prevails in the current therapies for treating allergic rhinitis. Despite good efficacy, some patients discontinue or reject SLIT because the treatment has a slow onset, and has no surveillance like SCIT. Poor compliance is a general challenge for prolonged medical treatments.

To cater to their needs, many molecules are in the pipeline to treat allergic rhinitis patients across the 7MM. Some major products are anticipated to hit the market during 2019-2032, including REGN5713-5714-5715 and Grass MATA.

Allergic Rhinitis (AR) Epidemiology

As the market is derived using a patient-based model, the Allergic Rhinitis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total prevalent cases of Allergic Rhinitis, Total diagnosed prevalent cases of Allergic Rhinitis, Age-specific diagnosed prevalent cases of Allergic Rhinitis, Severity-specific diagnosed prevalent cases of Allergic Rhinitis, and Allergen-specific diagnosed prevalent cases of Allergic Rhinitis in the 7MM covering, the United States, EU4 countries (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2019 to 2032.

• There were 178 million prevalent cases of Allergic Rhinitis estimated to have occurred in the 7MM in 2022 of which 47 million of the cases were estimated to be from the US alone and these cases are anticipated to increase during forecasted period.
• There were 89 million diagnosed prevalent cases of Allergic Rhinitis estimated to have occurred in the 7MM in 2022 of which 25 million of the accounted cases were estimated to be from the US alone and these cases are anticipated to grow in the foreseeable future during the study period.
• The diagnosed prevalent cases were further divided into severity specific cases. The severity-specific diagnosed prevalent cases of Allergic Rhinitis is further categorized into mild, moderate, and severe with 17 million, 51 million and 20 million cases respectively in the 7MM in 2022 which will further increase in future.
• The age specific cases of Allergic Rhinitis was divided into 0-10 years, 10-17 years ,18-59 years, 60 and above with 66% of the total cases were reported among 18-59 years age group in the 7MM.
• The allergen-specific diagnosed prevalent cases is further divided into grass pollen, mites, tree pollen, animal dander, fungal spores, and weed pollen. Grass pollen is the most prominent reasons for the allergen sensitization among AR patients.

Allergic Rhinitis (AR) Drug Chapters

The drug chapter segment of the Allergic Rhinitis report encloses a detailed analysis of Allergic Rhinitis late-stage and mid-stage (Phase-III and Phase-II) pipeline drug. It also helps to understand the Allergic Rhinitis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Emerging Drugs:

REGN5713-5714-5715: Regeneron Pharmaceuticals

REGN5713-5714-5715 is an investigational combination of three fully human monoclonal antibodies designed to treat allergic inflammatory conditions caused by the allergen Betv1, which is the main allergen responsible for birch pollen allergies. Birch allergy can trigger reactions such as allergic rhinitis and asthma. The Bet v1-specific mAbs (REGN5713, REGN5714, and REGN5715) were generated using Regeneron's VelocImmune platform. Preclinical studies demonstrated that the three mAbs bind independently and non-competitively to Bet v 1. All three together provided maximal inhibition of Bet v 1 binding to human polyclonal IgE and potently blocked basophil activation ex vivo and mast cell degranulation in vivo.

Grass MATA MPL: Allergy Therapeutics

Grass MATA MPL contains an extract of 13 grass pollens modified with glutaraldehyde to form allergoids that reduce the reactivity with immunoglobulin E (IgE) antibodies without a reduction in other important immunological properties, such as T-cell reactivity. The allergoid is adsorbed to microcrystalline tyrosine as a depot adjuvant system formulation. Monophosphoryl lipid-A (MPL) is included as an adjuvant to increase the immunogenic effect of the immunotherapy and to enhance the switch from an allergen-specific helper T-cell Type 2 (Th2) to helper T-cell Type 1 (Th1) like an immune response.

Detailed emerging therapies list will be provided in the final report.

Allergic Rhinitis (AR) Market Outlook

The management of AR involves allergen avoidance, pharmacotherapy, allergen-specific immunotherapy, or a combination of all three. Pharmacologic options include intranasal corticosteroids (INSs), oral and intranasal antihistamines, intranasal chromones, oral and intranasal decongestants, oral and intranasal anticholinergic agents, and anti-leukotrienes.

Potential off-label treatments for AR include:

Antihistamines, work well for treating allergy symptoms. They may be used when symptoms do not happen often or do not last long. Antihistamine nasal sprays work well for treating AR.

Corticosteroids: Nasal corticosteroid sprays are the most effective treatment for AR. They work best when used nonstop, but they can also be helpful for shorter periods. They can even help when used intermittently. Corticosteroid sprays are generally safe for children and adults. It must be noted that many brands are available in this treatment space, both off-label and prescription based.

Decongestants may also help reduce symptoms such as nasal stuffiness.

Other medicines include: Leukotriene inhibitors are prescription medicines that block leukotriene. These are the chemicals the body releases in response to an allergen that also triggers symptoms.

Allergy Shots (immunotherapy) includes regular shots of the pollen you are allergic to. Each dose is slightly larger than the dose before it until you reach the dose that helps control your symptoms. Allergy shots may help your body adjust to the pollen causing the reaction.

Sublingual Immunotherapy Treatment (SLIT): Instead of shots, medicine put under the tongue may help with grass and ragweed allergies

Immunotherapy with allergens has proven efficacy in the treatment of AR/asthma and allergy.

Therapies that have been approved in the 7MM, including XOLAIR by Novartis Pharmaceuticals (Japan), ODACTRA/ACARIZAX/MITICURE (SLIT-tablet) by ALK-Abello, GRASTEK/GRAZAX (Grass pollen allergy vaccine tablet) by ALK-Abello, ITULAZAX, RAGWITEK/RAGWIZAX, CEDARCURE by ALK-Abello, Stallergenes Greer's ACTAIR (STG320) and ORALAIR, Glenmark Pharmaceuticals' (RYALTRIS), BILAXTEN/BILANOA by FAES Farma/Taiho Pharmaceutical, RUPAFIN by Mitsubishi Tanabe Pharma Corporation, DESALEX by Kyorin Pharmaceutical Co, and ALLESAGA TAPE by Hisamitsu Pharmaceutical Co., Inc.(Japan)

In light of the above, some developmental initiatives have been taken toward the management of AR. The condition may evolve as some interesting therapies are heading down the pipeline. This would encourage reimbursement scenarios, doctors' adoption, and patient compliance. Some companies have initiated clinical trials investigating new treatment options, including Regeneron Pharmaceuticals' REGN5713-5714-5715 and Grass MATA by Allergy Therapeutics as the potential therapies lined up for forecast in the 7MM in the DelveInsight therapeutics market model.

• The total market size of allergy rhinitis in the 7MM is approximately USD 10,175 million in 2022 and is projected to increase during the forecast period (2023-2032)
• The market size in the 7MM will increase at a CAGR of about 2.2% due to increasing prevalence of the disease and launch of the emerging drug
• Among EU countries, Germany and France accounts for the maximum market size of USD 1,337 and USD 977 million in 2022 while Spain occupies the bottom of the ladder in the same year with USD 593 million.
• Japan accounts for market size of USD 2,284 million in 2022, but these dynamics are expected to change in the forecasted years.

Allergic Rhinitis (AR) Drug Uptake

This section focuses on the rate of uptake of the potential drug expected to get launched in the market during the study period 2019-2032. For example, we estimate that both drug (REGN5713-5714-5715 and Grass MATA) are expected to be launched in the year 2024 and 2026 in the US, respectively. Both drug are under development in the Phase III stage.

Further detailed analysis of emerging therapies drug uptake in the report…

Allergic Rhinitis (AR) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers detailed information on collaborations, acquisition and merger, licensing, and patent details for allergic rhinitis emerging therapies.

KOL- Views:

To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on allergic rhinitis evolving treatment landscape, patient reliance on conventional therapies, patient's therapy switching acceptability, drug uptake along with challenges related to accessibility, include the Division of Allergy and Immunology at the University of California in Irvine, USA; Division of Allergy, Immunology, and Rheumatology, Georgetown University Medical School, USA; Allergy Center, Department of Dermatology and Allergy, Berlin, Germany; University Paris-Saclay, France; Centre for Biomedical Investigation Network on Respiratory Diseases (CibeRes), Barcelona, Spain; Graduate School of Medicine, Chiba University, Japan, and Others.

DelveInsight's analysts connected with 50+ KOLs to gather insights, however, interviews were conducted with 15+ KOLs in the 7MM. Centers such as the Department of Allergy, Department of Immunology, etc. were contacted. Their opinion helps to understand and validate current and emerging therapies and treatment patterns or allergic rhinitis market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis, and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis is done to analyze multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy. In efficacy, the trial's primary and secondary outcome measures are evaluated.

Further, the safety of the drug is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Report:

• The report covers a segment of key events, an executive summary, descriptive overview of allergic rhinitis, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression along with treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging therapies along with the elaborative profiles of late-stage and prominent therapies will have an impact on the current treatment landscape.
• A detailed review of the allergic rhinitis market; historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM allergic rhinitis market.

Allergic Rhinitis (AR) Report Insights

• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Allergic rhinitis Market Size and Trends
• Existing and future Market Opportunity

Allergic Rhinitis (AR) Report Key Strengths

• 10 Years Forecast
• 7MM Coverage
• Allergic Rhinitis Epidemiology Segmentation
• Key Cross Competition
• Attribute analysis
• Drug Uptake and Key Market Forecast Assumptions

Allergic Rhinitis (AR) Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT and Attribute Analysis)

Key Questions:

Market Insights:

• What was the Allergic Rhinitis total market size, the market size by therapies, and market share (%) distribution in 2019, and how it would all look in 2032? What are the contributing factors for this growth?
• What will be the market share of different drugs in Allergic Rhinitis in the future?
• What will be the impact on the current market with the launch of emerging drug?
• How much market will be captured by Grass MATA MPL and REGN5713-5714-5715 after its launch?
• Which drug is going to be the largest contributor to the market in 2032?
• What are the pricing variations among different geographies for approved and off-label therapies?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What are the disease risk, burdens, and unmet needs of allergic rhinitis? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to allergic rhinitis?
• What is the historical and forecasted allergic rhinitis patient pool in the United States, EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan?
• How many patients are of mild, moderate and severe allergic rhinitis?
• What is the pool of Allergen specific cases of allergic rhinitis?
• What factors are affecting the diagnosis of allergic rhinitis?

Current Treatment Scenario, Marketed Drug, and Emerging Therapies:

• What are the current options for the standard of care of allergic rhinitis? What are the current treatment guidelines for the treatment of allergic rhinitis in the US and Europe?
• How many companies are developing therapies for the treatment of allergic rhinitis?
• How many emerging therapies are in the mid-stage and late stage of development for the treatment of allergic rhinitis?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
• What are the patents of emerging therapies for allergic rhinitis?
• What will be the impact on the market after the expected patent expiry of current branded drugs?
• What is the cost burden of marketed therapies on patients?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of recommended therapies? Focus on reimbursement policies.
• What are the 7MM historical and forecasted market of allergic rhinitis?

Reasons to buy:

The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the allergic rhinitis Market

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years
• To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Detailed analysis and potential of current and emerging therapies under the Conjoint analysis section to provide visibility around leading emerging drug.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs
• To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in future.
• Detailed insights on the unmet need of the existing market so that the upcoming players can strengthen their development and launch strategy.

Table of Contents

1. Key Insights

2. Report Introduction

3. AR Market Overview at a Glance

• 3.1. Market Share (%) Distribution of AR in 2019
• 3.2. Market Share (%) Distribution of AR in 2032

4. Epidemiology and Market Forecast Methodology

5. Key Events

6. Executive Summary of of AR

7. Disease Background and Overview of Allergic Rhinitis

• 7.1. Introduction
• 7.2. Classification of Rhinitis
• 7.3. Etiology
• 7.4. Pathogenesis
• 7.5. Signs and Symptoms
• 7.6. Complications of Allergic Rhinitis
• 7.7. Diagnosis
  • 7.7.1. Differential Diagnosis
  • 7.7.2. Diagnostic Guidelines
    • 7.7.2.1. Allergic Rhinitis: Clinical Practice Guideline by American Academy of Otolaryngology-Head and Neck Surgery, (Endorsed 2014, Reaffirmed, April 2020)
    • 7.7.2.2. Consensus Statement of the Italian Society of Pediatric Allergy and Immunology for the Pragmatic Management of Children And Adolescents With Allergic or Immunological Diseases During the COVID-19 Pandemic: 2020
    • 7.7.2.3. Recommendation for Clinical Practice Diagnostic and Therapeutic Management of Allergic Rhinitis by ENT: French Society of Oto-Rhino-Laryngology and Face and Neck Surgery, 2020
    • 7.7.2.4. Japanese Guidelines for Allergic Rhinitis: 2020
• 7.8. Treatment
  • 7.8.1. Treatment Guidelines
    • 7.8.1.1. Allergic Rhinitis: Clinical Practice Guideline by American Academy of Otolaryngology Head and Neck Surgery, (Endorsed 2014, Reaffirmed, April 2020)
    • 7.8.1.2. ARIA Guideline 2019: Treatment of Allergic Rhinitis in the German Health System
    • 7.8.1.3. British Society of Allergy and Clinical Immunology (BSACI) Guideline for the Diagnosis and Management of Allergic and Non-allergic Rhinitis (Revised Edition 2017)
    • 7.8.1.4. Consensus Statement of the Italian Society of Pediatric Allergy and Immunology for the Pragmatic Management of Children and Adolescents With Allergic or Immunological Diseases During the COVID-19 Pandemic: 2020
    • 7.8.1.5. Recommendation for Clinical Practice-Diagnostic and Therapeutic Management of Allergic Rhinitis by ENT: French Society of Oto-Rhino-Laryngology and Face and Neck Surgery, 2020
    • 7.8.1.6. Japanese Guidelines for Allergic Rhinitis: 2020

8. Epidemiology and Patient Population of AR

• 8.1. Key Findings
• 8.2. Assumptions and Rationale: The 7MM
  • 8.2.1. The United States
  • 8.2.2. EU4 and the United Kingdom
  • 8.2.3. Japan
• 8.3. Total Prevalent Cases of Allergic Rhinitis in the 7MM
• 8.4. Diagnosed Prevalent Cases of Allergic Rhinitis in the 7MM
• 8.5. The United States
  • 8.5.1. Prevalent cases of Allergic Rhinitis in the US
  • 8.5.2. Diagnosed Prevalent Cases of Allergic Rhinitis in the US
  • 8.5.3. Age-specific diagnosed prevalent cases of Allergic Rhinitis in the US
  • 8.5.4. Severity-specific diagnosed prevalent cases of Allergic Rhinitis in the US
  • 8.5.5. Allergen-specific diagnosed prevalent cases of Allergic Rhinitis in the US
• 8.6. EU4 Countries and the UK
  • 8.6.1. Prevalent cases of Allergic Rhinitis in EU4 and the UK
  • 8.6.2. Diagnosed prevalent cases of Allergic Rhinitis in EU4 and the UK
  • 8.6.3. Age-specific diagnosed prevalent cases of Allergic Rhinitis in EU4 and the UK
  • 8.6.4. Severity-specific diagnosed prevalent cases of Allergic Rhinitis in EU4 and the UK
  • 8.6.5. Allergen-specific diagnosed prevalent cases of Allergic Rhinitis in EU4 and the UK
• 8.7. Japan
  • 8.7.1. Prevalent cases of Allergic Rhinitis in Japan
  • 8.7.2. Diagnosed Prevalent Cases of Allergic Rhinitis in Japan
  • 8.7.3. Age-specific diagnosed prevalent cases of Allergic Rhinitis in Japan
  • 8.7.4. Severity-specific diagnosed prevalent cases of Allergic Rhinitis in Japan
  • 8.7.5. Allergen-specific diagnosed prevalent cases of Allergic Rhinitis in Japan

9. Patient Journey

10. Marketed Drugs

• 10.1. Key Cross
• 10.2. Sublivac: HAL Allergy Ltd.
  • 10.2.1. Product Description
  • 10.2.2. Regulatory Milestone
  • 10.2.3. Clinical Development
    • 10.3.2.1. Clinical Trial Information
  • 10.2.3. Safety and Efficacy
  • 10.2.4. Product Profile
• 10.3. Rupafin (Rupatidine fumarate ): Teikoku Seiyaku/Uriach
  • 10.3.1. Product Description
  • 10.3.2. Regulatory Milestone
  • 10.3.3. Other Development Activities
  • 10.3.4. Clinical Development
  • 10.3.5. Safety and Efficacy
  • 10.3.6. Product Profile
• 10.4. Allesaga Tape (Emedastine fumarate ): Hisamitsu Pharmaceutical
  • 10.4.1. Product Description
  • 10.4.2. Regulatory Milestone
  • 10.4.2. Clinical Development
  • 10.4.3. Safety and Efficacy
  • 10.4.4. Product Profile
• 10.5. Xolair (Omalizumab): Novartis Pharmaceuticals
  • 10.5.1. Product description
  • 10.5.2. Regulatory milestone
  • 10.5.3. Other development activities
  • 10.5.4. Clinical development
    • 10.5.4.1. Clinical trial information
  • 10.5.5. Safety and efficacy
  • 10.5.6. Product profile
• 10.6. Odactra/Acarizax/Miticure (House dust mite allergy immunotherapy [HDM SLIT-tablet]): ALK-Abello
  • 10.6.1. Product description
  • 10.6.2. Regulatory milestone
  • 10.6.3. Other development activities
  • 10.6.4. Clinical development
    • 10.6.4.1. Clinical trial information
  • 10.6.5. Safety and efficacy
    • 10.6.5.1. Summary of pivotal trial
  • 10.6.6. Product profile
• 10.7. Itulazax (SQ tree SLIT-tablet): ALK-Abello
  • 10.7.1. Product description
  • 10.7.2. Regulatory milestone
  • 10.7.3. Other development activities
  • 10.7.4. Clinical development
    • 10.7.4.1. Clinical trial information
  • 10.7.5. Safety and efficacy
    • 10.7.5.1. Summary of Pivotal Trial
  • 10.7.6. Product profile
• 10.8. Ragwitek/Ragwizax (Short Ragweed Pollen Allergen Extract): ALK-Abello
  • 10.8.1. Product description
  • 10.8.2. Regulatory milestone
  • 10.8.3. Other development activities
  • 10.8.4. Clinical development
    • 10.8.4.1. Clinical trial information
  • 10.8.5. Safety and efficacy
    • 10.8.5.1. Summary of Pivotal Trial
  • 10.8.6. Product profile
• 10.9. Cedarcure (Japanese Cedar Pollen Sublingual Tablets/TO-206): Torii Pharmaceutical/ALK-Abello
  • 10.9.1. Drug Description
  • 10.9.2. Regulatory Milestones
  • 10.9.3. Other Developmental Activities
  • 10.9.4. Safety and Efficacy
    • 10.9.4.1. Summary of pivotal trial
  • 10.9.5. Product profile
• 10.10. Actair (STG320): Stallergenes Greer
  • 10.10.1. Drug Description
  • 10.10.2. Regulatory Milestones
  • 10.10.3. Other Developmental Activities
  • 10.10.4. Clinical Development
  • 10.10.5. Safety and Efficacy
    • 10.10.5.1. Summary of pivotal trial
  • 10.10.6. Product Profile
• 10.11. Bilaxten/Bilanoa (Bilastine): FAES Farma/Taiho Pharmaceuticals
  • 10.11.1. Drug Description
  • 10.11.2. Regulatory Milestones
  • 10.11.3. Other Developmental Activities
  • 10.11.4. Clinical Development
  • 10.11.5. Safety and Efficacy
    • 10.1.1.1. Summary of a Pivotal Trial
  • 10.11.6. Product Profile
• 10.12. Ryaltris (Olopatadine Hydrochloride and Mometasone Furoate Monohydrate Nasal Spray): Glenmark Pharmaceuticals Inc.
  • 10.12.1. Drug Description
  • 10.12.2. Regulatory Milestones
  • 10.12.3. Other Developmental Activities
  • 10.12.4. Clinical Development
  • 10.12.5. Safety and Efficacy
  • 10.12.6. Product Profile

11. Emerging Drugs

• 11.1. Key Cross Competition
• 11.3. MG01 + T517: Inmunotek
  • 11.3.1. Product Description
  • 11.3.2. Clinical Development
  • 11.3.3. Clinical Trials Information
  • 11.3.4. Product Profile
  • 11.3.5. Analysts' Views
• 11.4. Norketotifen (NKT): Emergo Therapeutics
  • 11.4.1. Product Description
  • 11.4.2. Other Developmental Activities
  • 11.4.3. Clinical Development
  • 11.4.4. Clinical Trials Information
  • 11.4.5. Product profile
  • 11.4.6. Analysts' views
• 11.5. B244 suspension (AOB201): AOBiome LLC
  • 11.5.1. Product Description
  • 11.5.2. Other Developmental Activities
  • 11.5.3. Clinical Development
  • 11.5.4. Clinical Trials Information
  • 11.5.5. Safety and Efficacy
  • 11.5.6. Product profile
  • 11.5.7. Analysts' views
• 11.6. REGN5713-5714-5715: Regeneron Pharmaceuticals
  • 11.6.1. Product Description
  • 11.6.2. Other Developmental Activities
  • 11.6.3. Clinical Development
  • 11.6.4. Clinical Trials Information
  • 11.6.5. Product Profile
  • 11.6.6. Analysts' Views
• 11.7. IRL201104: Revolo Biotherapeutics
  • 11.7.1. Product Description
  • 11.7.2. Other Developmental Activities
  • 11.7.3. Clinical Development
  • 11.7.4. Clinical Trials Information
  • 11.7.5. Product Profile
  • 11.7.6. Analysts' Views
• 11.8. MM09-MG01: Inmunotek
  • 11.8.1. Product Description
  • 11.8.2. Clinical Developmental Activities
    • 11.8.2.1. Clinical Trial Information
  • 11.8.3. Product Profile
• 11.9. Grass MATA MPL: Allergy Therapeutics
  • 11.9.1. Product Description
  • 11.9.2. Clinical Development
    • 11.9.2.1. Clinical Trial Information
  • 11.9.3. Safety and Efficacy
  • 11.9.4. Product Profile
• 11.10. MG01-T521: Inmunotek S.L
  • 11.10.1. Product Description
  • 11.10.2. Clinical Development
    • 11.10.2.1. Clinical Trial Information
  • 11.10.3. Product Profile
• 11.11. MG56: Inmunotek S.L
  • 11.11.1. Product Description
  • 11.11.2. Clinical Development
    • 11.11.2.1. Clinical Trial Information
  • 11.11.3. Product Profile
• 11.12. Birch MATA MPL: Allergy Therapeutics
  • 11.12.1. Product Description
  • 11.12.2. Other Developmental Activities
  • 11.12.3. Clinical Development
  • 11.12.4. Product Profile

12. AR: Seven Major Market Analysis

• 12.1. Key Findings
• 12.2. Market Outlook
• 12.3. Key Market Forecast Assumptions
• 12.4. Attribute Analysis
• 12.5. Market Size of AR in the 7MM
• 12.6. Market Size of AR by Therapies in the 7MM
• 12.7. Market Size of AR in the United States
  • 12.7.1. Total Market Size of AR
  • 12.7.3. Market size of AR by therapies
• 12.8. Market Size of AR in EU4 and the UK
  • 12.8.1. Total Market Size of AR
  • 12.8.2. Market size of AR by therapies
• 12.9. Market Size of AR in Japan
  • 12.9.1. Total Market Size of AR
  • 12.9.2. Market size of AR by therapies

13. Key Opinion Leaders' Views

14. SWOT Analysis

15. Unmet needs

16. Market Access and Reimbursement

• 16.1. The United States
  • 16.1.1. Centers for Medicare & Medicaid Services (CMS)
• 16.2. In EU4 and the UK
  • 16.2.1. Germany
  • 16.2.2. France
  • 16.2.3. Italy
  • 16.2.4. Spain
  • 16.2.5. United Kingdom
• 16.3. Japan
  • 16.3.1. MHLW

17. Appendix

• 17.1. Bibliography
• 17.2. Acronyms and Abbreviations
• 17.3. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer